Welcome to our dedicated page for CELLECTAR BIOSC news (Ticker: CLRBZ), a resource for investors and traders seeking the latest updates and insights on CELLECTAR BIOSC stock.
The CLRBZ news page aggregates recent disclosures and media coverage related to Cellectar Biosciences, Inc., a late-stage clinical radiopharmaceutical and biotechnology company listed on NASDAQ under the symbol CLRB. Company communications describe Cellectar as focused on developing phospholipid-based targeted radiotherapeutics and radioconjugates for the treatment of cancer.
News items associated with CLRBZ and Cellectar typically cover updates on the company’s lead asset iopofosine I 131, an iodine-131 Phospholipid Drug Conjugate designed for hematologic and solid tumor cancers, as well as pipeline programs such as CLR 121125 (CLR 125), an iodine-125 Auger-emitting candidate for solid tumors, and CLR 121225 (CLR 225), an actinium-225 based candidate for pancreatic and other cancers. Coverage often includes clinical trial milestones, such as Phase 2b and Phase 1b study updates in Waldenstrom’s macroglobulinemia and pediatric high-grade glioma, and early-stage development plans in triple-negative breast cancer and pancreatic ductal adenocarcinoma.
Investors and observers can use this news feed to follow regulatory developments described by the company, including FDA designations like Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease, and Fast Track, as well as EMA PRIME and orphan designations. Announcements may also highlight guidance from the European Medicines Agency’s Scientific Advice Working Party on potential Conditional Marketing Authorization pathways, along with information on isotope supply agreements and clinical research partnerships.
By reviewing the CLRBZ news page, readers can track how Cellectar characterizes progress across its PDC-based radiotherapeutic pipeline, including scientific presentations, preclinical data releases, financing transactions, and collaboration agreements that the company reports as supporting its oncology programs.
Cellectar (NASDAQ: CLRB) reported 2025 results and corporate updates on March 4, 2026, highlighting regulatory progress for iopofosine I-131, initiation of a Phase 1b study for CLR 125 in triple negative breast cancer, and patent and supply agreements to support its radiotherapeutic pipeline.
Financials: cash of $13.2M at year-end; full-year net loss of $21.8M; R&D and G&A both ~$11.5M.
Cellectar Biosciences (NASDAQ: CLRB) will report full year financial results for the period ended December 31, 2025, and host a corporate update and conference call on Wednesday, March 4, 2026 at 8:30 a.m. Eastern Time.
The event will be accessible by toll-free dial-in and webcast; a replay of the presentation will be available on the company’s Investor Relations Events page.
Cellectar Biosciences (NASDAQ: CLRB) expanded its global intellectual property estate with newly issued patents across Europe, Asia-Pacific, the Middle East, and the Americas. The patents cover iopofosine I 131, CLR-125, imaging of cancer stem cells, and fractionated dosing regimens.
The company said this strengthens protection ahead of a planned 3Q26 filing for conditional marketing authorization of iopofosine I 131 with the European Medicines Agency.
Cellectar (NASDAQ: CLRB) outlined 2026 priorities at the Biotech Showcase and plans to submit a Conditional Marketing Authorization (CMA) application to the EMA for iopofosine I 131 in Waldenstrom’s macroglobulinemia in 3Q 2026, targeting potential European approval in early 2027. The company noted FDA Breakthrough Designation and a confirmed traditional accelerated approval pathway in the U.S. for iopofosine I 131, highlighted Phase 2 CLOVER WaM final results and subset analyses, and expects to begin dosing in the Phase 1b CLR 125 TNBC study in 1Q 2026 with interim data due mid-2026. Cellectar reported raising approximately $15.2M to support pipeline and regulatory work.
Cellectar Biosciences (NASDAQ: CLRB) announced a multi-year supply agreement with Ionetix to secure clinical- and commercial-scale cGMP-grade Actinium-225 (Ac-225) and Astatine-211 (At-211) for development of targeted alpha therapies, including the phospholipid radioconjugate CLR-225 for solid tumors.
Ionetix will install a second cyclotron at its Michigan facility, with one cyclotron dedicated to Ac-225 and the other to At-211, aiming to provide a dependable, scalable isotope supply for clinical trials and potential commercial launches.
Cellectar (NASDAQ: CLRB) reported Q3 2025 results and a corporate update on Nov 13, 2025. Key clinical and regulatory progress includes SAWP/EMA advice confirming eligibility to seek a Conditional Marketing Authorization (CMA) for iopofosine I-131 in post-BTKi refractory Waldenstrom macroglobulinemia with a planned CMA submission in 2026, ongoing plans for an NDA to FDA for accelerated approval (subject to funding), and receipt of rare pediatric drug designation for inoperable relapsed/refractory pediatric high-grade glioma. The company initiated a Phase 1b CLR 125 study in TNBC and completed IND-enabling work for CLR 225 with an Ac-225 supply agreement. Financials: $12.6M cash at 9/30/25, net loss $4.4M for Q3, and recent fundraising of approximately $12.7M.
Cellectar Biosciences (NASDAQ: CLRB) will report third quarter financial results for the period ended September 30, 2025 and provide a corporate update on Thursday, November 13, 2025 at 8:30 a.m. Eastern Time.
The company will host a conference call and webcast for investors and analysts; a replay of the corporate presentation will be available in the Events section of the company’s Investor Relations website.
Cellectar Biosciences (NASDAQ: CLRB) announced on October 27, 2025 that the U.S. FDA granted Rare Pediatric Disease Designation for iopofosine I 131 in inoperable relapsed or refractory pediatric high-grade glioma (r/r pHGG).
Interim CLOVER-2 Phase 1b data presented at AACR showed that patients receiving a minimum total administered dose of 55 mCi (n=6) experienced average PFS 5.4 months and OS 8.6 months (ongoing). Three patients receiving ≥4 infusions showed average PFS 8.1 months and OS 11.5 months (ongoing), with two objective responses. No treatment-related deaths were reported; safety events were primarily hematologic and manageable.
Cellectar Biosciences (NASDAQ: CLRB) presented preclinical data for CLR 225 at the AACR Special Conference on Pancreatic Cancer Research (Sept 28–Oct 1, 2025). The poster reported that CLR 225, an actinium-based alpha-emitter, completed IND-enabling studies and showed meaningful inhibition of tumor growth or reduced tumor volume across three pancreatic ductal adenocarcinoma xenograft models (PANC-1, MIA PaCa-2, BxPC-3).
The program demonstrated predictable, linear biodistribution, was well tolerated in dosing studies with no body-weight loss, and showed no toxicities in GLP toxicity studies; the company retains the option to advance to a Phase 1 first-in-human study.
Cellectar Biosciences (NASDAQ:CLRB) announced agreements with institutional investors resulting in the immediate exercise of existing warrants and gross proceeds of approximately $5.8 million prior to placement agent fees and offering expenses. An aggregate of 1,048,094 existing warrants were exercised.
In the transactions, holders paid $5.25 per existing warrant and $0.125 per new warrant, receiving 1,048,094 Series I and 1,048,094 Series II new unregistered warrants exercisable at $6.00. Series I term: 5 years; Series II term: 18 months. Net proceeds will fund working capital, the Phase 1b CLR 121125 trial in triple-negative breast cancer, and preparation of a CMA filing with the European Medicines Agency. The company will file a registration statement covering resale of shares issuable upon exercise.